Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 14/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.48 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202587 | 0.82 | NISCH (0.48) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL28428254 | 0.80 | NISCH (0.60) | NISCHTOP2ATOP2B | |
| SCHEMBL5476725 | 0.80 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL6992574 | 0.80 | NISCH (0.72) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL4680644 | 0.78 | NISCH (0.45) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL9375560 | 0.78 | NISCH (0.61) | NISCH | |
| SCHEMBL9579892 | 0.76 | NISCH (0.81) | NISCH | |
| SCHEMBL105024 | 0.74 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL10507263 | 0.74 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL2288651 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | claimed |
| US-4440919-A | CROSSLINKED WITH RESONANCE FREE DI(ALKENE TERTIARY AMINE) CYCLIC COMPOUNDS | BAUSCH & LOMB INCORPORATED (US) | 1984-04-03 | — | — | US | claimed |
| US-4436887-A | CONTACT LENSES, OXYGEN PERMEABILITY | BAUSCH & LOMB INCORPORATED (US) | 1984-03-13 | — | — | US | claimed |
| EP-0079720-A2 | Low n-vinyl lactam content-based biomedical devices and process for preparation thereof | BAUSCH & LOMB INCORPORATED (US) | 1983-05-25 | — | — | EP | claimed |
| EP-0079721-A2 | N-vinyl lactam-based biomedical devices and process for preparation thereof | BAUSCH & LOMB INCORPORATED (US) | 1983-05-25 | — | — | EP | claimed |
| EP-4720161-A1 | CORE-SHEATH MICROSTRUCTURES, PROCESS OF PREPARING SAME AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078220-A1 | CORE-SHEATH MICROSTRUCTURES, PROCESS OF PREPARING SAME AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-03-19 | — | — | US | disclosed |
| WO-2024246913-A1 | CORE-SHEATH MICROSTRUCTURES, PROCESS OF PREPARING SAME AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-12-05 | — | — | WO | disclosed |
| US-11572429-B2 | Hydrogels based on vinyl-caprolactam | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) | 2023-02-07 | — | — | US | disclosed |
| CN-109843897-B | Hydrogen generation from formic acid by metal complex catalysis under amine-free and aqueous conditions | 阿卜杜拉国王科技大学 | 2021-12-03 | — | — | CN | disclosed |
| US-11014079-B2 | Hydrogen generation from formic acid catalyzed by a metal complex under amine-free and aqueous conditions | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-05-25 | — | — | US | disclosed |
| US-11014079-B2 | Hydrogen generation from formic acid catalyzed by a metal complex under amine-free and aqueous conditions | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-05-25 | — | — | US | disclosed |
| US-4870145-A | Process for preparing polymeric beads | BAUSCH & LOMB INCORPORATED (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0331507-A1 | Polyvinyl chloride plastisol composition | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4804410-A | WITH ORGANOSULFUR COMPOUNDS, AMINES OR AMMONIA, HYPOPHOSPHORUS ACID STABILITY, HEAT RESISTANCE HYDRIDE; | ISHIHARA CHEMICAL CO., LTD. (JP) | 1989-02-14 | — | — | US | disclosed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | disclosed |
| US-4440919-A | CROSSLINKED WITH RESONANCE FREE DI(ALKENE TERTIARY AMINE) CYCLIC COMPOUNDS | BAUSCH & LOMB INCORPORATED (US) | 1984-04-03 | — | — | US | disclosed |
| US-4436887-A | CONTACT LENSES, OXYGEN PERMEABILITY | BAUSCH & LOMB INCORPORATED (US) | 1984-03-13 | — | — | US | disclosed |
| EP-0079721-A2 | N-vinyl lactam-based biomedical devices and process for preparation thereof | BAUSCH & LOMB INCORPORATED (US) | 1983-05-25 | — | — | EP | disclosed |
| EP-0079720-A2 | Low n-vinyl lactam content-based biomedical devices and process for preparation thereof | BAUSCH & LOMB INCORPORATED (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078220-A1 | CORE-SHEATH MICROSTRUCTURES, PROCESS OF PREPARING SAME AND USES THEREOF | SRM, SMS, ADM2 | NISCH 1826/4885LMNA 1605/4885RECQL 2979/4885 |
| US-11014079-B2 | Hydrogen generation from formic acid catalyzed by a metal complex under amine-free and aqueous conditions | HAO2, APEX1, ME3 | NISCH 444/4885LMNA 3916/4885RECQL 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.